Literature DB >> 14706080

Invasive aspergillosis: current and future challenges in diagnosis and therapy.

W W Hope, D W Denning.   

Abstract

Invasive aspergillosis is an increasingly common disease. While there have been significant advances in the past decade, significant challenges remain in terms of diagnosis and therapy. Some of the recent advances are outlined and future opportunities to improve the unacceptable mortality that is currently associated with this infection are considered.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14706080     DOI： 10.1111/j.1469-0691.2004.00809.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN： 1198-743X            Impact factor:   8.067


  11 in total

1.  Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis.

Authors:  Donna M MacCallum; Julie A Whyte; Frank C Odds
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

2.  Monoclonal antibodies to hyphal exoantigens derived from the opportunistic pathogen Aspergillus terreus.

Authors:  Ajay P Nayak; Brett J Green; Erika Janotka; Justin M Hettick; Sherri Friend; Steve J Vesper; Detlef Schmechel; Donald H Beezhold
Journal:  Clin Vaccine Immunol       Date:  2011-07-06

3.  Prospective Biomarker Screening for Diagnosis of Invasive Aspergillosis in High-Risk Pediatric Patients.

Authors:  Juergen Loeffler; Julia Hafner; Carlo Mengoli; Clemens Wirth; Claus Peter Heussel; Claudia Löffler; P Lewis White; Andrew J Ullmann; Denise Michel; Verena Wiegering; Matthias Wölfl; Paul Gerhardt Schlegel; Hermann Einsele; Jan Springer; Matthias Eyrich
Journal:  J Clin Microbiol       Date:  2016-12-28       Impact factor: 5.948

4.  Workload due to Aspergillus fumigatus and significance of the organism in the microbiology laboratory of a general hospital.

Authors:  E Bouza; J Guinea; T Peláez; J Pérez-Molina; L Alcalá; P Muñoz
Journal:  J Clin Microbiol       Date:  2005-05       Impact factor: 5.948

5.  Activation of platelets by Aspergillus fumigatus and potential role of platelets in the immunopathogenesis of Aspergillosis.

Authors:  Ernst Kristian Rødland; Thor Ueland; Turid M Pedersen; Bente Halvorsen; Fredrik Muller; Pål Aukrust; Stig S Frøland
Journal:  Infect Immun       Date:  2009-12-14       Impact factor: 3.441

6.  Fungal biomass is a key factor affecting polymorphonuclear leucocyte-induced hyphal damage of filamentous fungi.

Authors:  Charalampos Antachopoulos; Joanne P Demchok; Emmanuel Roilides; Thomas J Walsh
Journal:  Mycoses       Date:  2009-07-22       Impact factor: 4.377

Review 7.  Mycoses in the elderly.

Authors:  H Hof
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-11-13       Impact factor: 3.267

8.  Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose- dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis.

Authors:  Vidmantas Petraitis; Ruta Petraitiene; William W Hope; Joseph Meletiadis; Diana Mickiene; Johanna E Hughes; Margaret P Cotton; Theodouli Stergiopoulou; Miki Kasai; Andrea Francesconi; Robert L Schaufele; Tin Sein; Nilo A Avila; John Bacher; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2009-03-23       Impact factor: 5.191

9.  Flaws in design, analysis and interpretation of Pfizer's antifungal trials of voriconazole and uncritical subsequent quotations.

Authors:  Karsten J Jørgensen; Helle Krogh Johansen; Peter C Gøtzsche
Journal:  Trials       Date:  2006-01-19       Impact factor: 2.279

10.  Treatment with etanercept and low monocyte concentration contribute to the risk of invasive aspergillosis in patients post allogeneic stem cell transplantation.

Authors:  Tamara Zoran; Michael Weber; Jan Springer; P Lewis White; Joachim Bauer; Annika Schober; Claudia Löffler; Bastian Seelbinder; Kerstin Hünniger; Oliver Kurzai; André Scherag; Sascha Schäuble; C Oliver Morton; Hermann Einsele; Jörg Linde; Jürgen Löffler
Journal:  Sci Rep       Date:  2019-11-21       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.